Debio

Debiopharm is an independent biopharmaceutical company focused on developing therapies to establish new standards of care in oncology and infectious diseases. The company engages in the in-licensing of innovative compounds, their comprehensive development through clinical testing, and subsequent out-licensing. Beyond drug development, Debiopharm also encompasses drug manufacturing and makes strategic investments in digital health and smart data start-ups, contributing to a holistic approach in improving patient outcomes.

The company was founded in 1979 by Dr. Rolland-Yves Mauvernay, driven by the insight that many promising therapeutic products were prematurely abandoned. He established Debiopharm to identify and advance these compounds into viable medicines, utilizing a model of in-licensing for development and out-licensing for commercialization. Dr. Mauvernay, along with his son Thierry Mauvernay, built the organization on this principle, emphasizing robust clinical validation.

Debiopharm’s efforts are directed towards patients suffering from cancer and infectious diseases, aiming to provide improved treatment options and enhance their quality of life. The company envisions a future where its contributions lead to the establishment of tomorrow's standard of care across its therapeutic areas. Through sustained development and strategic investments, Debiopharm strives to deliver lasting value in global healthcare.